Generic Rytary Availability
Last updated on Sep 10, 2026.
Rytary is a brand name of carbidopa/levodopa, approved by the FDA in the following formulation:
| Manufacturer | Approval date | Strengths [RLD] |
|---|---|---|
| IMPAX | January 7, 2015 |
|
Has a generic version of Rytary been approved?
Yes, the following Rytary generics have been approved by the FDA:
Authorized generic versions| Company | NDC Code Number | Formulation |
|---|---|---|
| REMEDYREPACK INC. | 705184610 |
Carbidopa and Levodopa ORAL CAPSULE, EXTENDED RELEASE 61.25; 245 mg/1; mg |
| REMEDYREPACK INC. | 705184618 |
Carbidopa and Levodopa ORAL CAPSULE, EXTENDED RELEASE 23.75; 95 mg/1; mg |
| REMEDYREPACK INC. | 705184621 |
Carbidopa and Levodopa ORAL CAPSULE, EXTENDED RELEASE 48.75; 195 mg/1; mg |
| REMEDYREPACK INC. | 705184630 |
Carbidopa and Levodopa ORAL CAPSULE, EXTENDED RELEASE 36.25; 145 mg/1; mg |
| Zydus Pharmaceuticals USA Inc. | 707102139 |
Carbidopa and Levodopa ORAL CAPSULE, EXTENDED RELEASE 23.75; 95 mg/1; mg |
| Zydus Pharmaceuticals USA Inc. | 707102140 |
Carbidopa and Levodopa ORAL CAPSULE, EXTENDED RELEASE 36.25; 145 mg/1; mg |
| Zydus Pharmaceuticals USA Inc. | 707102141 |
Carbidopa and Levodopa ORAL CAPSULE, EXTENDED RELEASE 48.75; 195 mg/1; mg |
| Zydus Pharmaceuticals USA Inc. | 707102142 |
Carbidopa and Levodopa ORAL CAPSULE, EXTENDED RELEASE 61.25; 245 mg/1; mg |
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rytary. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Generic Rytary prices
Pricing information is not currently available. While the medication may be approved, it does not appear to be commercially available at this time. Market launch delays can occur. For the most accurate and up-to-date information, consider contacting the manufacturer.
Patent protection
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development. These patents may include claims related to the drug's formulation, manufacturing process, or other aspects.
| Patent Title | Controlled release formulations of levodopa and uses thereof |
|---|---|
| Patent Number | 8,377,474 |
| Issue Date | February 19, 2013 |
| Inventor | Hsu Ann & Kou Jim H. & Alani Laman |
| Current Assignee | Impax Laboratories, Inc. |
| Patent Description |
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid...
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
|
| Patent Expiry Dates |
|
| Patent Title | Controlled release formulations of levodopa and uses thereof |
|---|---|
| Patent Number | 8,454,998 |
| Issue Date | June 4, 2013 |
| Inventor | Hsu Ann & Kou Jim H. & Alani Laman |
| Current Assignee | Impax Laboratories, Inc. |
| Patent Description |
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid...
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
|
| Patent Expiry Dates |
|
| Patent Title | Controlled release formulations of levodopa and uses thereof |
|---|---|
| Patent Number | 8,557,283 |
| Issue Date | October 15, 2013 |
| Inventor | Hsu Ann & Kou Jim H. & Alani Laman Lynn |
| Current Assignee | Impax Laboratories, Inc. |
| Patent Description |
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid...
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
|
| Patent Expiry Dates |
|
| Patent Title | Controlled release formulations of levodopa and uses thereof |
|---|---|
| Patent Number | 9,089,607 |
| Issue Date | July 28, 2015 |
| Inventor | Hsu Ann & Kou Jim H. & Alani Laman Lynn |
| Current Assignee | Impax Laboratories, Inc. |
| Patent Description |
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid...
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
|
| Patent Expiry Dates |
|
| Patent Title | Controlled release formulations of levodopa and uses thereof |
|---|---|
| Patent Number | 9,089,608 |
| Issue Date | July 28, 2015 |
| Inventor | Hsu Ann & Kou Jim H. & Alani Laman Lynn |
| Current Assignee | Impax Laboratories, Inc. |
| Patent Description |
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid...
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
|
| Patent Expiry Dates |
December 26, 2028
Drug Product: Yes |
| Patent Title | Controlled release formulations of levodopa and uses thereof |
|---|---|
| Patent Number | 9,463,246 |
| Issue Date | October 11, 2016 |
| Inventor | Hsu Ann & Kou Jim H. & Alani Laman Lynn |
| Current Assignee | Impax Laboratories, Inc. |
| Patent Description |
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid...
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
|
| Patent Expiry Dates |
December 26, 2028
Patent Use: TREATMENT OF PARKINSON'S DISEASE Drug Product: Yes |
| Patent Title | Controlled release formulations of levodopa and uses thereof |
|---|---|
| Patent Number | 9,533,046 |
| Issue Date | January 3, 2017 |
| Inventor | Hsu Ann & Kou Jim & Alani Laman |
| Current Assignee | Impax Laboratories, Inc. |
| Patent Description |
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid...
The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
|
| Patent Expiry Dates |
December 26, 2028
Patent Use: TREATMENT OF PARKINSON'S DISEASE Drug Product: Yes |
| Patent Title | Controlled release formulations of levodopa and uses thereof |
|---|---|
| Patent Number | 9,901,640 |
| Issue Date | February 27, 2018 |
| Inventor | Hsu; Ann & Kou; Jim & Alani; Laman |
| Current Assignee | Impax Laboratories, Inc. (Hayward, CA) |
| Patent Description |
A modified release levodopa dosage form.
|
| Patent Expiry Dates |
December 26, 2028
Patent Use: TREATMENT OF PARKINSON'S DISEASE Drug Product: Yes |
More about Rytary (carbidopa / levodopa)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (35)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: dopaminergic antiparkinsonism agents
- En español
Patient resources
Other brands
Sinemet, Crexont, Sinemet CR, Dhivy, ... +2 more
Professional resources
Other brands
Sinemet, Crexont, Sinemet CR, Dhivy, ... +2 more
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
